Myobloc Shortage: What Providers and Prescribers Need to Know in 2026

Myobloc (rimabotulinumtoxinB) is the only FDA-approved botulinum toxin type B product in the United States. Despite the absence of an FDA-listed shortage in 2026, your patients who require Myobloc face significant structural access barriers — from restrictive insurer step therapy policies to limited pharmacy stocking. This guide outlines what clinicians need to know to proactively manage access for affected patients.

Clinical Context: Who Needs Myobloc?

Myobloc is FDA-approved for two indications: (1) treatment of cervical dystonia to reduce severity of abnormal head position and neck pain in adults, and (2) treatment of chronic sialorrhea in adults. It is uniquely valuable for a specific patient subset:

Patients who have developed neutralizing antibodies to type A botulinum toxins (immunoresistance)

Patients with inadequate response to type A toxins despite optimized dosing

Patients with documented intolerance or allergy to type A formulations

Myobloc cleaves VAMP/synaptobrevin rather than SNAP-25 (the target of type A toxins), giving it mechanistic independence from type A resistance. It is available in three vial sizes: 2,500 Units/0.5 mL, 5,000 Units/1 mL, and 10,000 Units/2 mL — all at 5,000 U/mL concentration. Unlike type A products, it does not require reconstitution.

Dosing Reference

Cervical dystonia: Initial dose of 2,500–5,000 units divided among affected cervical muscles (prior botulinum toxin history); lower for toxin-naive patients. Most treatment sessions: ≤12,500 units. Repeat every 12 weeks or as clinically indicated.

Chronic sialorrhea: 2,500 or 3,500 units injected intraglandularly into the parotid and submandibular glands.

Unit dosing is NOT interchangeable with any type A botulinum toxin product. The FDA mandated distinct non-proprietary names for all botulinum toxins in 2009 precisely to prevent dosing errors. A commonly cited conversion ratio of 50:1 (Myobloc:Botox units) is referenced in some insurer policies but is not FDA-endorsed.

Insurance and Prior Authorization Landscape

The insurance landscape for Myobloc is restrictive. Key points prescribers should know:

Medicare: Myobloc is currently not covered by any Medicare plan — neither Part B nor Part D. This represents a significant access barrier for elderly patients with cervical dystonia.

Commercial insurance: Prior authorization is required by essentially all commercial plans. Initial authorization is typically valid for 6 months; renewals are annual.

Step therapy: Major insurers (Aetna, Cigna, BCBS, Regence, Moda, EOCCO and others) require documented trial and failure of alternative botulinum toxins — typically Botox, Dysport, and Xeomin — before authorizing Myobloc. Aetna, for instance, explicitly requires ineffective response or intolerance to all three before approval.

Documentation requirements: Chart notes must document diagnosis, functional impairment, specific muscles involved, prior botulinum toxin history and outcomes, and rationale for Myobloc specifically.

Strategies to Support Patient Access

Document type A resistance meticulously. Insurance appeals for Myobloc are much easier with a clear clinical record showing diminishing response over time, antibody testing if performed, and documented trials with specific type A products including doses and outcomes.

Begin the PA process early. PA approval for Myobloc can take weeks, particularly for new patients or those with complex insurer step therapy. Submit documentation at least 4–6 weeks before the planned treatment date.

Know the manufacturer copay program. Eligible commercially insured patients may pay $0 for Myobloc up to $4,000/year. Refer patients who face cost barriers to the Myobloc copay program (call 1-888-461-2255 or visit myobloc.com).

Stock in-office when possible. For practices regularly treating cervical dystonia, purchasing Myobloc directly and administering it in-office can bypass retail/specialty pharmacy access barriers entirely. Work with your distributor to establish a reliable procurement channel.

Direct patients to medfinder for pharmacy location help. For patients who need to source Myobloc through a pharmacy, medfinder.com/providers offers a referral pathway so your team can connect patients directly with pharmacy availability search.

When to Consider Therapeutic Alternatives

For patients whose access barriers cannot be resolved, consider whether a type A toxin (Botox, Dysport, Xeomin, Daxxify) could be an appropriate alternative — particularly for patients who are type A naive or have only partial resistance. For Medicare-covered patients who cannot receive Myobloc, Botox (covered under Part B for cervical dystonia) may be the most accessible option. A detailed comparison is available in our post: Alternatives to Myobloc.

Key Takeaways for Prescribers

Myobloc is not in active FDA shortage in 2026, but structural access barriers remain significant

No Medicare coverage; commercial PA required with step therapy at most major insurers

Manufacturer copay program available for commercially insured patients ($0 up to $4,000/year)

In-office stocking is the most reliable access pathway for high-volume botulinum toxin practices

Start PA 4–6 weeks before planned injection; document type A resistance thoroughly

For a provider-specific guide to helping patients find Myobloc at a pharmacy, visit medfinder for providers.